The Biotech Voyager

Jeff Martin
  • 0.0 (0)
  • News Commentary
  • Daily

Biotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.

  1. 3d ago

    Cell and gene therapies are coming back into focus...

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. The best way to support the show - check out our sponsor! 👇 This episode is brought to you by LabThread. Use the code VOYAGER3 to 3 months FREE (on a 12 month plan) labthread.com

  2. Oct 30

    Anthropic Acquires a 1-Person Therapeutic Company, ARPHA-H GIVE Program Highlight, and Much More...

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to 3 months FREE (on a 12 month plan)

  3. Oct 28

    Insilico Medicine is BACK, New Genetic Medicines ROAR, and a New Segment Debuts...

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to 3 months FREE (on a 12 month plan)

  4. Oct 23

    AI Proteins Get (Up to) $400M, Icelandic Biotech Takes Off, and Orphan Drugs Acellerators

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to get a special discount at labthread.com

  5. Oct 21

    The Key to Treating Autism, Gene Therapy in the Kidney, and other Funding!

    Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they're big news. This broadcast is brought to you by LabThread. Get a 3 month trial at labthread.com using code VOYAGER3

  6. Oct 14

    Tuesday, October 13

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to get a special discount at labthread.com

  7. Oct 2

    October Starts with a Massive List of Biotech Signals!

    Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to get a special discount at labthread.com

  8. Sep 26

    BigHat Raises $75M, a Parkinson’s Vaccine & Engineered Red Blood Cells

    Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities and emerging technologies. From AI-powered antibody discovery to neutrophil cell therapies, the conversation spans cutting-edge innovation while maintaining critical scientific scrutiny. The episode opens with Big Hat Biosciences' impressive $75 million Series C raise, examining their AI-driven platform for antibody drug conjugate development. The hosts explore how Big Hat's cyclical approach integrates automated wet lab experimentation with AI analysis to iteratively improve therapeutic candidates. The discussion contextualizes AI's role in drug discovery, distinguishing between AI for molecular design versus AI for data analysis and experimental optimization. With backing from major pharmaceutical companies including Amgen, BMS, Eli Lilly, and Merck, and fresh patient dosing in Phase I trials, Big Hat represents a significant validation signal for AI-enabled therapeutic development. The conversation continues with Basecamp Research's massive $140 million Series C, exploring their Eden AI model trained on 9.7 trillion nucleotide tokens from ethically sourced genomic data across 30+ countries. The hosts examine how this comprehensive genetic diversity dataset could enable more effective in vivo CAR-T therapies for solid tumors by identifying candidates with broader patient population applicability. The discussion probes the technical challenges of translating genomic data into functional therapeutics while acknowledging the ambitious nature of in vivo cell therapy approaches. Additional signals include AvenCell's $47 million raise for their universal switchable CAR-T platform, which achieved 71% overall response rates in relapsed/refractory AML using adapter molecules that can target multiple antigens. The hosts examine Scarlet Therapeutics' DARPA-funded program developing smart red blood cells that sense environmental conditions and deliver therapeutics accordingly. Lyft Therapeutics emerges from rebranding with neutrophil cell therapies, though the hosts express significant skepticism about the six to twelve hour lifespan challenge inherent to neutrophil-based therapeutics. AC Immune's active immunotherapy for Parkinson's demonstrates 100% antibody response rates at 100 weeks, prompting debate about terminology distinctions between vaccines and active immunotherapies. The episode features an interview with Ryan from LabThread discussing laboratory software challenges and the future of lab automation, followed by examination of Anthropic's Claude-led discovery of a potential new gene editing mechanism and the A16Z Academy as an alternative to traditional university education for aspiring biotech professionals. Listeners will gain insight into how AI is transforming both therapeutic development and laboratory operations, the critical importance of therapeutic lifespan in cell therapy design, the evolving role of government funding through programs like DARPA and ARPA-H, and why the distinction between prophylactic vaccines and therapeutic active immunotherapies matters for understanding emerging modalities. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #AI #drugdiscovery #CARTtherapy #genetherapy #antibodies #celltherapy #activeimmunotherapy #labautomation

See All (52)

About

Biotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.

Information

  • Creator
    Jeff Martin
  • Years Active
    2026
  • Episodes
    52
  • Rating
    Clean

You Might Also Like